Seminars in Oncology
Volume 33, Issue 5 , Pages 563-575 , October 2006

Prognostic Factors in Renal Cell Carcinoma

  • Brian M. Shuch

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
    • ,
  • John S. Lam

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
    • Corresponding Author InformationAddress correspondence to John S. Lam, MD, Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, 10833 Le Conte Ave, 66-118 CHS, Box 951738, Los Angeles, CA 90095, USA.
    • ,
  • Arie S. Belldegrun

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
    • ,
  • Robert A. Figlin

      Affiliations

    • Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA.
    • Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Beckman Research Institute, and Comprehensive Cancer Center, Duarte, CA.

References 

  1. Jemal A, Siegal R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Lam JS, Leppert JT, Figlin RA, et al. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005;6:7–18
  3. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3 (Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)). Cancer. 1997;80:992–993
  4. Giuliani L, Giberti C, Martorana G, et al. Radical extensive surgery for renal cell carcinoma: Long-term results and prognostic factors. J Urol. 1990;143:468–473
  5. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am. 2003;30:467–480
  6. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162:1930–1933
  7. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996;155:1868–1873
  8. Sobin LH, Wittekind C. In: TNM Classification of Malignant Tumours. (ed 6).. New York, NY: Wiley-Liss; 2002;p. 193
  9. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171:2181–2185
  10. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004;171:1066–1070
  11. Frank I, Blute ML, Leibovich BC, et al. Independent validation of the 2002 American Joint Committee on Cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005;173:1889–1892
  12. Cheville JC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinmoa: Pathological features associated with cancer specific survival. J Urol. 2001;166:453–456
  13. Ficarra V, Guille F, Schips L, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer. 2005;104:2116–2123
  14. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–1095
  15. Frank I, Blute ML, Leibovich BC, et al. pT2 classification for renal cell carcinoma (Can its accuracy be improved?). J Urol. 2005;173:380–384
  16. Lam JS, Patard JJ, Goel RH, et al. Can pT2 classification for renal cell carcinoma be improved? (An international multicenter experience). J Urol. 2006;175(suppl):240–241
  17. Lam JS, Patard JJ, Goel RH, et al. Significance of tumor size in locally advanced renal cell carcinoma (pT3a): An international multicenter experience. J Urol. 2006;175(suppl):234
  18. Han KR, Bui MH, Pantuck AJ, et al. TNM T3a renal cell carcinoma: Adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003;169:899–903
  19. Thompson RH, Leibovich BC, Cheville JC, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?. J Urol. 2005;173:918–921
  20. Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104:53–60
  21. Lam JS, Patard JJ, Leppert JT, et al. Prognostic significance of T3a renal cell carcinoma with adrenal gland involvement: an international multicenter experience. J Urol. 2005;173(suppl):269–270
  22. Thompson RH, Leibovich BC, Cheville JC, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol. 2005;174:1218–1221
  23. Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pT3 renal cell carcinoma—Can the 2002 primary tumor classification be improved?. J Urol. 2005;173:716–719
  24. Kim HL, Zisman A, Han KR, et al. Prognostic significance of venous thrombus in renal cell carcinoma (Are renal vein and inferior vena cava involvement different?). J Urol. 2004;171:588–591
  25. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension (Is all T3b the same?). J Urol. 2004;171:598–601
  26. Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94:33–41
  27. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes (Impact on survival and benefits of immunotherapy). Cancer. 2003;97:2995–3002
  28. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169:2076–2083
  29. Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68–72
  30. Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: Review of 130 cases. J Urol. 1979;122:306–309
  31. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol. 1990;144:243–245
  32. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther. 2004;4:1081–1096
  33. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet. 1999;353:14–17
  34. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  35. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 2001;358:966–970
  36. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol. 2004;171:1071–1076
  37. Montie JE, Stewart BH, Straffon RA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117:272–275
  38. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993;150:463–466
  39. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol. 1978;120:148–152
  40. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540
  41. Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: Identification of prognostic factors and patient survival. J Urol. 1988;139:1173–1176
  42. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3(suppl 1):S92–S97
  43. Mani S, Todd MB, Katz K, et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154:35–40
  44. Seaman E, Goluboff ET, Ross S, et al. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology. 1996;48:692–695
  45. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314–319
  46. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–663
  47. Bretheau D, Lechevallier E, de Fromont M, et al. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76:2543–2549
  48. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1 (Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)). Cancer. 1997;80:987–989
  49. Chao D, Zisman A, Pantuck AJ, et al. Collecting duct renal cell carcinoma: Clinical study of a rare tumor. J Urol. 2002;167:71–74
  50. Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma (The seventh sickle cell nephropathy). Am J Surg Pathol. 1995;19:1–11
  51. Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–595
  52. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65:5628–5637
  53. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  54. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–624
  55. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol. 2005;23:2763–2771
  56. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376–2381
  57. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488–495
  58. Farrow GM, Harrison EG, Utz DC. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. Cancer. 1968;22:556–563
  59. Goldstein NS. The current state of renal cell carcinoma grading (Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)). Cancer. 1997;80:977–980
  60. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523–528
  61. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol. 2001;25:275–284
  62. Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer. 2000;89:604–614
  63. Bertoni F, Ferri C, Benati A, et al. Sarcomatoid carcinoma of the kidney. J Urol. 1987;137:25–28
  64. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol. 2002;168:2395–2400
  65. Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005;103:2517–2525
  66. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104:511–520
  67. Van Poppel H, Vandendriessche H, Boel K, et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol. 1997;158:45–49
  68. Goncalves PD, Srougi M, Dall’lio MF, et al. Low clinical stage renal cell carcinoma: Relevance of microvascular tumor invasion as a prognostic parameter. J Urol. 2004;172:470–474
  69. Uzzo RG, Cherullo EE, Myles J, et al. Renal cell carcinoma invading the urinary collecting system: Implications for staging. J Urol. 2002;167:2392–2396
  70. Palapattu GS, Pantuck AJ, Dorey F, et al. Collecting system invasion in renal cell carcinoma: Impact on prognosis and future staging strategies. J Urol. 2003;170:768–772
  71. Terrone C, Cracco C, Guercio S, et al. Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol. 2004;46:472–476
  72. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997;158:1691–1695
  73. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–1657
  74. Kim HL, Han KR, Zisman A, et al. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol. 2004;171:1810–1813
  75. Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: Implications for prognosis. J Urol. 2003;170:1742–1746
  76. Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000;86:203–207
  77. Gogus C, Baltaci S, Filiz E, et al. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology. 2004;63:447–450
  78. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986;136:376–379
  79. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988;48:7310–7313
  80. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–296
  81. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–841
  82. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group. Clin Cancer Res. 2004;10:6310S–6314S
  83. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d’Immunotherapie. Ann Oncol. 2002;13:1460–1468
  84. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463
  85. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–67
  86. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–4566
  87. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. J Clin Oncol. 2004;22:3316–3322
  88. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: A multicenter European study. Cancer. 2005;104:1362–1371
  89. Vasselli JR, Shih JH, Iyengar SR, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A. 2003;100:6958–6963
  90. Tan MH, Rogers CG, Cooper JT, et al. Gene expression profiling of renal cell carcinoma. Clin Cancer Res. 2004;10:6315S–6321S
  91. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10:5464–5471
  92. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496–1501
  93. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173:1853–1862
  94. Lam JS, Leppert JT, Figlin RA, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005;66:1–9
  95. Harris AL. Hypoxia—A key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47
  96. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62–S67
  97. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  98. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423–427
  99. Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol. 2003;170:593–594
  100. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158:905–919
  101. Lidgren A, Hedberg Y, Grankvist K, et al. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 2005;11:1129–1135
  102. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811
  103. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714–3721
  104. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–1320
  105. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90
  106. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94:1569–1575
  107. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676
  108. Leppert JT, Lam JS, Yu H, et al. Targeting the vascular endothelial growth factor pathway in renal cell carcinoma, a tissue array based analysis. J Clin Oncol. 2005;23(suppl):386s
  109. Lam JS, Leppert JT, Yu H, et al. Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma. In: J Clin Oncol. 2005;23(suppl):387s
  110. Lane DP. Cancer (p53, guardian of the genome). Nature. 1992;358:15–16
  111. Moch H, Sauter G, Gasser TC, et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res. 1997;25(suppl 1):S25–S30
  112. Zigeuner R, Ratschek M, Rehak P, et al. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: A systematic analysis of primary and metastatic tumor tissue. Urology. 2004;63:651–655
  113. Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173:725–728
  114. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology. 1998;51:1057–1061
  115. Lee CT, Genega EM, Hutchinson B, et al. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. Urol Oncol. 2003;21:179–184
  116. Itoi T, Yamana K, Bilim V, et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004;90:200–205
  117. Mizutani Y, Nakanishi H, Yamamoto K, et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol. 2005;23:448–454
  118. Srinivasula SM, Datta P, Fan XJ, et al. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem. 2000;275:36152–36157
  119. Migita T, Oda Y, Naito S, et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002;94:973–979
  120. Hedberg Y, Ljungberg B, Roos G, et al. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer. 2003;88:1417–1423
  121. Pantuck AJ, Seligson DB, Wu H, et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Urol. 2005;173(suppl):96
  122. Seligson DB, Pantuck AJ, Liu X, et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004;10:2659–2669
  123. Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res. 2005;11:226–231

 Supported in part by the Richard and Nancy Bloch Kidney Cancer Research Fund.

PII: S0093-7754(06)00272-7

doi: 10.1053/j.seminoncol.2006.06.006

Seminars in Oncology
Volume 33, Issue 5 , Pages 563-575 , October 2006

Article Tools